EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Lower mortality risk associated with remdesivir plus corticosteroids vs corticosteroids alone for the treatment of patients hospitalized with SARS-CoV-2 infection in the early and later Omicron periods

Alpesh N Amin, Thomas Oppelt iD, Aastha Chandak iD, Robert L Gottlieb, Chidinma Chima-Melton, Natasha N Pettit, Andre C Kalil

American Journal of Health-System Pharmacy · 2026

DOI: 10.1093/ajhp/zxag034 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift American Journal of Health-System Pharmacy, 2026. Verfasst von Alpesh N Amin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine, University of California Irvine, Irvine, CA, USA. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose a risk to vulnerable populations. This retrospective study compared the effectiveness of remdesivir plus corticosteroids (CCS) versus CCS alone in patients hospitalized with COVID-19 from December 2021 to December 2024.

Methods

Data were extracted from a large, geographically-diverse US Premier Healthcare Database for adults hospitalized for COVID-19. Exclusion criteria included pregnancy, incomplete data, transfer from another hospital or hospice care, death/discharge during the baseline period, elective procedure admissions, patients without supplemental oxygen in hospitals that did not report charges for low-flow oxygen, and patients on extracorporeal membrane oxygenation. Propensity score matching was used to balance the distribution of underlying confounders in the two treatment groups. A Cox proportional hazards model was used to assess time to 14- and 28-day inpatient all-cause mortality.

Results

A total of 104,900 patients were initiated on remdesivir plus CCS and 66,016 were initiated on CCS alone in the first 2 days of hospitalization. Unadjusted 14- and 28-day mortality rates were lower for remdesivir-treated patients versus patients who did not receive remdesivir during hospitalization. Remdesivir plus CCS initiation upon admission for COVID-19 (in the total population) was associated with a significantly lower mortality rate (P < 0.0001) (in the overall Omicron period) at both 14 and 28 days, with an adjusted hazard ratio (95% confidence interval) of 0.77 (0.74-0.80) and 0.79 (0.77-0.82), respectively, versus CCS alone. Results were similar for the total population in the early and later Omicron periods.

Conclusion

Remdesivir plus CCS was associated with a significant reduction in inpatient all-cause mortality relative to CCS alone in patients hospitalized for COVID-19 across 3 years of the Omicron period, illustrating the utility of the most recent real-world evidence to help inform treatment recommendations for inpatient providers treating patients with SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateAlanineCOVID-19 Drug TreatmentAntiviral AgentsAdrenal Cortex HormonesCOVID-19HumansRetrospective StudiesFemaleMiddle AgedMaleAgedHospitalizationDrug Therapy, CombinationUnited StatesHospital MortalityAdult

Stichwörter der Autor:innen

SARS-CoV-2corticosteroidsmortalityreal-world evidenceremdesivir

Substanzen

remdesivirAdenosine MonophosphateAlanineAntiviral AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Medicine, School of Medicine, University of California Irvine, Irvine, CA, USA.
  • Medical Affairs, Gilead Sciences, Foster City, CA, USA.
  • Evidence and Access, Certara, Radnor, PA, USA.
  • Department of Internal Medicine, Baylor University Medical Center, Baylor Scott & White Health, Dallas, TX, USA.
  • Burnett School of Medicine at TCU, Fort Worth, TX, USA.
  • Cardiopulmonary Division, Pipeline Health, Los Angeles, CA.

ORCID-Profile: Thomas Oppelt, Aastha Chandak

Zitieren

APA

Amin, A. N., Oppelt, T., Chandak, A., Gottlieb, R. L., Chima-Melton, C., Pettit, N. N., & Kalil, A. C. (2026). Lower mortality risk associated with remdesivir plus corticosteroids vs corticosteroids alone for the treatment of patients hospitalized with SARS-CoV-2 infection in the early and later Omicron periods. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxag034

Vancouver

Amin AN, Oppelt T, Chandak A, Gottlieb RL, Chima-Melton C, Pettit NN, et al. Lower mortality risk associated with remdesivir plus corticosteroids vs corticosteroids alone for the treatment of patients hospitalized with SARS-CoV-2 infection in the early and later Omicron periods. American Journal of Health-System Pharmacy. 2026. doi:10.1093/ajhp/zxag034

BibTeX
@article{Amin2026,
  author = {Amin, Alpesh N and Oppelt, Thomas and Chandak, Aastha and Gottlieb, Robert L and Chima-Melton, Chidinma and Pettit, Natasha N and Kalil, Andre C},
  title = {Lower mortality risk associated with remdesivir plus corticosteroids vs corticosteroids alone for the treatment of patients hospitalized with SARS-CoV-2 infection in the early and later Omicron periods},
  journal = {American Journal of Health-System Pharmacy},
  year = {2026},
  doi = {10.1093/ajhp/zxag034}
}
Kostenlos starten →